About
Crossbridge Bio develops non-opioid pain relief therapies using monoclonal antibodies that target the Nav1.7 sodium channel.
Explore Crossbridge Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.